Skip to main content
SpringerLink
Log in

Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom

Ein prognostischer Marker für die histologische Diagnostik

Standardized determination of tumor-infiltrating lymphocytes in breast cancer

A prognostic marker for histological diagnosis

  • Schwerpunkt: Immunpathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Tumorinfiltrierende Lymphozyten (TIL) wurden in verschiedenen klinischen Studienkohorten als Prognoseparameter für das Mammakarzinom identifiziert.

Ziel der Arbeit

Ziel dieser Übersicht ist es, einen Überblick über den Stand der klinischen und der analytischen Validierung der TILs beim Mammakarzinom zu geben.

Material und Methoden

Standardisierte Guidelines der internationalen TIL Working Group sowie klinische und translationale Untersuchungen werden zusammengefasst.

Ergebnisse und Diskussion

Mammakarzinome mit einem erhöhten TIL-Infiltrat haben eine verbesserte Ansprechrate auf eine neoadjuvante Chemotherapie. Triplenegative und HER2-positive Mammakarzinome mit einem vermehrten TIL-Infiltrat weisen eine bessere Prognose auf. TILs sind ein neuer Prognoseparameter beim Mammakarzinom, der in der Routinediagnostik bestimmbar ist.

Abstract

Background

Tumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer.

Objectives

The aim of this review article is to provide an overview on the clinical and analytical validation of TILs in breast cancer.

Materials and methods

Summary of international guidelines of the TIL working group as well as clinical and translational studies.

Results, Conclusions

Breast carcinomas with a high TIL level have an improved response to neoadjuvant chemotherapy. Triple-negative and HER2-positive carcinomas with increased TIL levels have improved survival. TILs are a new prognostic biomarker for routine histopathological diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Moore OS Jr, Foote FW Jr. (1949) The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 2(4):635–642

    Article  Google Scholar 

  2. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Hrsg) (2012) IARC classifications, 4. Aufl. WHO classification of tumours of the breast, Bd. 4

    Google Scholar 

  3. Rigaud C, Theobald S, Noël P, Badreddine J, Barlier C, Delobelle A et al (1993) Medullary carcinoma of the breast. A multicenter study of its diagnostic consistency. Arch Pathol Lab Med 117(10):1005–1008

    CAS  PubMed  Google Scholar 

  4. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40–50

    Article  Google Scholar 

  5. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97–111

    Article  CAS  Google Scholar 

  6. Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Györffy B et al (2015) Classical pathology and mutational load of breast cancer – integration of two worlds. J Pathol Clin Res 1(4):225–238

    Article  CAS  PubMed Central  Google Scholar 

  7. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486–541

    Article  PubMed Central  Google Scholar 

  8. Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W et al (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24(11):2786–2793

    Article  CAS  Google Scholar 

  9. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113

    Article  CAS  Google Scholar 

  10. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al (2015) International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271

    Article  CAS  Google Scholar 

  11. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, International Immuno-Oncology Biomarker Working Group on Breast Cancer, – (2017) Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ. Semin Cancer Biol 52(Pt 2):16–25. (A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer). https://doi.org/10.1016/j.semcancer.2017.10.003

    PubMed  Google Scholar 

  12. https://www.tilsinbreastcancer.org

  13. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immunooncology Biomarkers working group. Adv Anat Pathol 24(5):235–251 (Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research)

    Article  PubMed Central  Google Scholar 

  14. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immuno-oncology Biomarkers working group. Adv Anat Pathol 24(6):311–335 (Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and Mesothelioma, Endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors)

    Article  Google Scholar 

  15. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J et al (2011) International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664

    Article  CAS  PubMed Central  Google Scholar 

  16. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG et al (2013) International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897–1906

    Article  PubMed Central  Google Scholar 

  17. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL et al (2016) Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2:16014. https://doi.org/10.1038/npjbcancer.2016.14

    Article  PubMed  PubMed Central  Google Scholar 

  18. Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer JU et al (2015) Standardized Ki67 diagnostics using automated scoring – clinical validation in the Gepartrio breast cancer study. Clin Cancer Res 21(16):3651–3657

    Article  CAS  Google Scholar 

  19. Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S et al (2016) Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29(10):1155–1164

    Article  CAS  Google Scholar 

  20. https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/

  21. Curigliano G, Burstein HJ, Winer PE, Gnant M, Dubsky P, Loibl S et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28(8):1700–1712

    Article  CAS  Google Scholar 

  22. https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/Gesamt_deutsch/Alle_aktuellen_Empfehlungen_2018.pdf

  23. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P et al (2013) Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 19(10):2775–2786

    Article  CAS  Google Scholar 

  24. Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y (2018) Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER+ breast cancer. J Natl Cancer Inst 110(2):166–175. https://doi.org/10.1093/jnci/djx137

    Article  Google Scholar 

  25. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C et al (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128–2139

    Article  Google Scholar 

  26. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352 (Apr)

    Article  CAS  PubMed Central  Google Scholar 

  27. Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218

    Article  PubMed Central  Google Scholar 

  28. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C et al (2015) Tumor-infiltrating lymphocytes and associations with pathological complete response and event free survival in HER2-positive early-stage breast cancer treated with Lapatinib and Trastuzumab: a secondary analysis of the NeoALTTO trial. Jama Oncol 1(4):448–454

    Article  PubMed Central  Google Scholar 

  29. Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A (2015) Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26(8):1698–1704

    Article  CAS  PubMed Central  Google Scholar 

  30. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R et al (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2‑positive and triple-negative primary breast cancers. J Clin Oncol 33(9):983–991

    Article  CAS  Google Scholar 

  31. Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C et al (2018) Tumor-infiltrating lymphocytes in patients receiving Trastuzumab/Pertuzumab-based chemotherapy: a TRYPHAENA Substudy. J Natl Cancer Inst 92:S15. https://doi.org/10.1016/S0959-8049(18)30283-1

    Article  Google Scholar 

  32. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860–867

    Article  CAS  Google Scholar 

  33. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D et al (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544–1550

    Article  CAS  Google Scholar 

  34. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966

    Article  PubMed Central  Google Scholar 

  35. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL (2016) Association of Stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 Adjuvant trial in patients with early-stage HER2-positive breast cancer. Jama Oncol 2(1):56–64

    Article  PubMed Central  Google Scholar 

  36. Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E et al (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18(1):52–62

    Article  CAS  Google Scholar 

  37. Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C et al (2016) Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the international TILs working group. Ann Surg Oncol 23(7):2242–2248

    Article  Google Scholar 

  38. Kojima YA, Wang X, Sun H, Compton F, Covinsky M, Zhang S (2018) Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014. Ann Diagn Pathol 35:77–79

    Article  Google Scholar 

  39. Tramm T, Di Caterino T, Jylling AB, Lelkaitis G, Lænkholm AV, Ragó P et al (2018) Scientific Committee of Pathology, Danish Breast Cancer Group (DBCG). Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. Acta Oncol 57(1):90–94

    Article  Google Scholar 

  40. Cabuk FK, Aktepe F, Kapucuoglu FN, Coban I, Sarsenov D, Ozmen V (2018) Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer. Indian J Pathol Microbiol 61(2):181–186

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland

    C. Denkert, J. Budczies, S. Wienert & F. Klauschen

  2. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Standort Berlin, Berlin, Deutschland

    C. Denkert

  3. German Breast Group, Neu-Isenburg, Deutschland

    S. Loibl

  4. VMscope GmbH, Berlin, Deutschland

    S. Wienert

  5. Institut für Pathologie, Universität Heidelberg, Heidelberg, Deutschland

    J. Budczies

Authors
  1. C. Denkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Loibl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Budczies
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Wienert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Klauschen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Denkert.

Ethics declarations

Interessenkonflikt

C. Denkert, S. Loibl, J. Budczies, S. Wienert und F. Klauschen geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Schwerpunktherausgeber

W. Roth, Mainz

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Denkert, C., Loibl, S., Budczies, J. et al. Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom. Pathologe 39, 520–531 (2018). https://doi.org/10.1007/s00292-018-0530-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-018-0530-y

Schlüsselwörter

Keywords

Search

Navigation